عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Media Minister: Saudi History Exhibition Establishes Relationship between Saudi Media, National History

Minister of Media Salman bin Yousef Al-Dosari at the exhibition. SPA
Minister of Media Salman bin Yousef Al-Dosari at the exhibition. SPA
TT
TT

Media Minister: Saudi History Exhibition Establishes Relationship between Saudi Media, National History

Minister of Media Salman bin Yousef Al-Dosari at the exhibition. SPA
Minister of Media Salman bin Yousef Al-Dosari at the exhibition. SPA

The Minister of Media and Chairman of the Board of Directors of the Saudi Press Agency (SPA), Salman bin Yousef Al-Dosari, expressed the Saudi media’s pride in its national message and its responsibility to consolidate the historical depth of the Saudi state by introducing its achievements, nobility, and cultural and social heritage, and promoting its civilizational achievement and regional and global status so that the progress march continues towards a promising future for the nation and the citizens under the Saudi Vision 2030.

He made his remarks following the opening on Wednesday of “Saudi Arabia's History Exhibition” at the headquarters of SPA in Riyadh. He noted that this documentary initiative aims to enrich historical knowledge and highlights the prosperous present of the country, within a framework that reflects the image of the Kingdom on the world stage.

He added that SPA’s holding of an exhibition on Saudi Arabia's history comes in the context of its national media role and to enrich its educational and knowledgeable message through an interactive media presentation, in a new experience for visitors from inside and outside the Kingdom, applying an innovative method that establishes a relationship between the media institution and the Kingdom's history.

The minister of media reiterated that the exhibition embodies the depth of the media’s connection with Saudi Arabia's history.

Nearly a century ago, the Kingdom witnessed the publication of Umm Al-Qura newspaper in 1924, in which it documented events and the reality of the national scene in its various aspects then. The issue of September 23, 1932 announced the declaration of all parts of the Kingdom united, under the name "Kingdom of Saudi Arabia,” marking a new era of development and modernization of the media sector, the diversity of its mass-media organizations, and the breadth of its message, keeping pace with the latest technologies across various media platforms.

After his statement, the minister of media extended his thanks and appreciation to the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and Prince Mohammed bin Salman bin Abdulaziz, Crown Prince and Prime Minister, for their support to Saudi media, and their continued interest in developing it, to enhance its role in highlighting the Kingdom's movement, under the goals of Saudi Vision 2030.

Most Viewed

 
 
Varieties

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”